Adelaide Research & Scholarship

Please use this identifier to cite or link to this item:
http://hdl.handle.net/2440/72540

Citations

Scopus

Web of Science®

Altmetric

?

?

Full metadata record

DC Field

Value

Language

dc.contributor.author

Kumeria, T.

en

dc.contributor.author

Kurkuri, M.

en

dc.contributor.author

Diener, K.

en

dc.contributor.author

Parkinson, L.

en

dc.contributor.author

Losic, D.

en

dc.date.issued

2012

en

dc.identifier.citation

Biosensors & Bioelectronics, 2012; 35(1):167-173

en

dc.identifier.issn

0956-5663

en

dc.identifier.issn

1873-4235

en

dc.identifier.uri

http://hdl.handle.net/2440/72540

-

dc.description.abstract

In this report, a label-free reflectometric interference spectroscopy (RIfS) based microchip biosensor for the detection of circulating tumour cells (CTCs) is demonstrated. Highly ordered nanoporous anodic aluminium oxide (AAO) fabricated by electrochemical anodization of aluminium foil was used as the RIfS sensing platform. Biotinylated anti-EpCAM antibody that specifically binds to human cancer cells of epithelial origin such as pancreatic cancer cells (PANC-1) was covalently attached to the AAO surface through multiple surface functionalization steps. Whole blood or phosphate buffer saline spiked with low numbers of pancreatic cancer cells were successfully detected by specially designed microfluidic device incorporating an AAO RIfS sensor, without labour intensive fluorescence labelling and/or pre-enhancement process. Our results show that the developed device is capable of selectively detecting of cancer cells, within a concentrations range of 1000-100,000 cells/mL, with a detection limit of <1000 cells/mL, a response time of <5 min and sample volume of 50 μL of. The presented RIfS method shows considerable promise for translation to a rapid and cost-effective point-of-care diagnostic device for the detection of CTCs in patients with metastatic cancer.